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The relaxin-like RXFP1 ligand–receptor system has important functions in tumor growth
and tissue invasion. Recently, we have identified the secreted protein, CTRP8, a member
of the C1q/tumor necrosis factor-related protein (CTRP) family, as a novel ligand of the
relaxin receptor, RXFP1, with functions in brain cancer. Here, we review the role of CTRP
members in cancers cells with particular emphasis on CTRP8 in glioblastoma.
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Relaxin-Like Peptides and Cognate Receptors in Cancer: A Brief
Overview
Most of the cellular and molecular mechanisms involved in RXFP1-mediated cancer promotion
have been established in breast, thyroid, and prostate cancer models. For more detailed reviews on
relaxin-like peptides and their cognate receptors, the reader is referred to recent excellent reviews (1–
5). Increased expression of relaxin-like peptides has been detected in breast cancer (6, 7). Using the
ERα-positive human breast cancer cell line MCF-7, the group of Mario Bigazzi showed that highly
purified porcine relaxin acted in a dose- and time-dependent manner and promoted proliferation
only with short-term exposure at low concentrations. Long-term exposure over up to 7 days reduced
proliferation and promoted differentiation of MCF-7 cells as demonstrated with up-regulation
of cell surface protein E-cadherin (8, 9). This was accompanied by an increase in inducible NO
synthase activity and intracellularNOproduction (10). In co-culturewithmyoepithelial cells, relaxin
enhanced ultrastructural signs of MCF-7 cell differentiation (11). Exposure to human recombinant
RLN2 for 24 h induced S100A4 expression and increased cell migration in ERα-negativeMDA-MB-
231 triple-negative breast cancer cells, but exposure for more than 3 days downregulated S100A4
levels and reduced cell migration and invasiveness in the same cell model in an RXFP1-dependent
manner, leading to reduced tumor xenograft growth in vivo (12). In an in vitro brain metastasis
model, RLN2 promoted the invasion of RXFP1-expressing MCF-7 human breast cancer cells into
brain tissue slices (13). These data suggest concentration-, time-, and cell context-dependent actions
of relaxin in breast cancer and an essential role for RXFP1 in mediating cell motility and invasion.
Increased expression of RLN2 and RXFP1 was also shown in thyroid cancer. RLN2/RXFP1
signaling promotes thyroid cancer motility and invasiveness. RXFP1 mediated the motility-
enhancing effect of RLN2 via induction of S100A4 in human thyroid carcinoma cells and
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RLN2 enhanced thyroid xenograft angiogenesis (14). RLN2/
RXFP1 signaling increased the expression and secretion of the
lysosomal proteinases, cathepsin-D and cathepsin-L, resulting in
enhanced elastinolytic activity and cell invasion through elastin
matrices (15). RXFP1 activation by RLN2 in human thyroid
cancer cells increased cell migration and extracellular matrix
invasion resulting from enhanced collagenolytic activity through
the upregulation of MMP2 and MT1-MMP/MMP14 and the
increased secretion of MMP2 (16).
In prostate cancer, RLN2/RXFP1 signaling increased cellmigra-
tion and proliferation in androgen-receptor (AR)-dependent
LNCaP and AR-independent PC3 prostate cancer cells (17) and
promoted growth in xenografts derived of androgen-independent
PC3 prostate cancer cells (18). The siRNA-mediated knockdown
of RXFP1 prevented the RLN2-induced increase in prostate can-
cer cell proliferation and invasiveness and induced apoptosis
(19). Injection of siRNA-loaded biodegradable nanoparticles into
xenografts of AR-positive LNCaP cells and AR-negative PC3 cells
downregulated RXFP1 and resulted in a significant reduction
in tumor proliferation and metastasis, implicating RXFP1 as an
important growth and survival factor in prostate cancer (20).
RXFP1-dependent and RLN2-induced proliferation of prostate
carcinoma cells was mediated via a PI3K/Akt signaling pathway.
Simultaneous blocking of protein kinase A (PKA) and NF-κB sig-
naling almost completely abolished RLN2-mediated proliferation
and colony formation in LNCaP cells (21). The extracellular N-
terminal low density lipoprotein A (LDL-A) module of RXFP1
was shown to reduce S100A4, S100P, IGFBP2, andMUC1 expres-
sion and inhibit RXFP1-mediated proliferation and invasion of
PC3 prostate cancer cells. Similar to RXFP1 knockdown in PC3
cells, LDL-A expression reduced pAKTT308 and decreased cell
proliferation and colony formation, suggesting LDL-A to block
activation of endogenous RXFP1 in PC3 cells (22).
The established role of RXFP1 in cancer and other diseases has
prompted attempts to identify specific agonists and antagonists of
RXFP1. A recent large high-throughput screen of small molecule
libraries yielded RXFP1 agonists (23, 24). The challenging search
for RXFP1 antagonists has so far produced few promising candi-
dates. The conversion of the two arginine residues (B13, B17) to
lysines (ΔH2) within the receptor binding domain of the B-chain
of humanRLN2 (“GRELVR”) was shown to reduce bioactivity and
cAMP production in RXFP1-positive myelo-monocytic THP1
cells and RXFP1 expressing HEK293 cells. This ΔH2 mutant
was able to bind to RXFP1 and function as a partial antagonist
to functional RLN2 in an in vivo xenograft model of prostate
cancer (25). In MCF-7 cancer cells and renal myofibroblasts
endogenously expressing relaxin, the ΔH2 analog blocked RXFP1
activation and significantly inhibited RLN2-induced MCF-7 cell
migration (26). When a chemically synthesized ΔH2 antago-
nist, named AT-001, was used alone or in combination with
the anti-mitotic taxane drug docetaxel, xenografts derived from
PC3 androgen-independent prostate cancer cells were reported to
show a dramatic 60 and 90% reduction in growth, respectively
(18). Although these are promising results, the vulnerability of
peptide antagonists to proteolytic attack, size restrictions limiting
their tissue penetration, and the difficulty in chemically synthe-
sizing large amounts of ΔH2 derivatives remains challenge. Our
recent discovery of a novel RXFP1 ligand that is structurally
distinct from relaxin-like peptides may provide new opportuni-
ties for developing RXFP1 antagonists. We identified C1q/tumor
necrosis factor-related protein (CTRP) family member CTRP8
as a novel RXFP1 ligand. Importantly, a small competitor pep-
tide derived from the closely related C1q/tumor necrosis factor-
related factor 6 (CTRP6) was able to disrupt the CTRP8-induced
and RXFP1-dependent migration of human glioma cells (27).
This suggests a novel and as yet poorly understood regula-
tory network in which C1q/tumor necrosis factor-related factors,
depending on the presence of resident secreting cells, can mod-
ulate RXFP1 functions in a tissue-dependent and tumor-specific
manner.
Tissue Distribution and Structure of CTRP
Family Members
The family of complement C1q/tumor necrosis factor-related pro-
teins is composed of adiponectin and 16CTRPmembers (CTRP1-
9, 9B, 10 15). All CTRPs are secreted proteins that get assem-
bled into trimers and higher-order oligomers. In co-expression
systems, CTRPs can also form heteromeric complexes (28–30).
The C-terminal globular domain of CTRPs shares close similarity
with the 3D structure of the complement component C1q and
the tumor necrosis factor (TNF) homology domain present in
members of the TNF family (31–33). Unlike adiponectin, which is
produced at high level and almost exclusively by adipocytes, many
CTRP members have broad expression profiles. CTRP members
were shown to be expressed in various tissues and cell types (28,
34–45). Of particular interest for this review is CTRP8 detected by
PCR in the testis and lung (29).
The structure of CTRPs is highly conserved during vertebrate
evolution as determined by sequence comparison of orthologous
CTRPs from zebrafish, frog, mouse, and human genomes (46).
All CTRPs share a common protein structure with adiponectin,
with CTRP9 showing the highest homology (54%) in the globular
C1q domain to adiponectin (30). Ctrp8 and Ctrp9B are both
pseudogenes in the mouse genome (29). The structure of CTRPs
consists of four distinct domains (Figure 1A). The N-terminal
signal peptide facilitates protein secretion and is followed by a
short variable region. The variable region contains one or more
conserved cysteine (Cys) residues, which create disulfide bonds
to facilitate higher-order multimeric protein assembly and/or
secretion (28, 30, 46–49). Next, a collagen-like domain contains a
variable number of Gly-X–Y (where X and Y indicate any amino
acid; often Y is a proline or hydroxyproline) repeats, which are
essential for the formation of a left-handed coiled coil structure
composed of three collagen-like chains. This collagen triple helix
acts as a stabilizing stalk for the formation of CTRP trimers
(Figure 1B) (32). Located at the C-terminus of each collagen-
like domain is a jelly-roll β-sandwich folded globular domain with
3D structural homology to complement component C1q and the
tumor necrosis factor ligand family, hence the name CTRP (28,
45, 46, 50). Connected by the collagenous stalk, three such C1q-
like protomers form the globular head typical for CTRPmembers.
The collagen domain not only facilitates trimer formation but
also contributes to multimerization of CTRPs into bouquet-like
quaternary structures (Figure 1C) (32, 51). CTRP4 is unique
among the secreted members of the C1qTNF family as it lacks
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FIGURE 1 | Structure of CTRP family members. (A) Domain structure of a
single CTRP protomer, which is composed of a signal peptide (SP), variable
region (V), collagen domain (Col – Gly-X-Y), and globular C1q/TNF domain;
(B) CTRP are secreted and can form homotrimers; (C) trimers can form
higher-order multimeric 3D structures composed of multiple trimers.
the collagen domain but, instead, contains two tandem globular
C1q domains connected by a short non-conserved 18 amino
acid linker. CTRP4 protein is encoded by a single exon and its
globular C1q domain shows highest homology (44%) to the CTRP
member C1qDC1/Caprin-2 (52). The crystal structure of CTRP5
identified residues Y152, F230, andV232 within the globular domain
as important contributors to the trimer formation and these
residues are highly conserved among C1q family proteins (29, 33,
51). Exceptions are CTRP1Y230 and CTRP6H230 and CTRP8H230
where the phenylalanine residue F230 of CTRP5 is replaced by
less hydrophobic His (H) or Tyr (Y) residues, suggesting poten-
tial differences in trimerization and complex stability (51). This
finding is intriguing for three reasons: (i) phylogenetic analysis
of currently known C1q globular domains of C1q-like family
members identified a close relationship of CTRP members 1, 6,
and 8 (33, 53); (ii) CTRP1 and CTRP8 share an identical peptide
sequence identified as a binding motif for the relaxin receptor
RXFP1 (54, 55), and (iii) we described CTRP8 as a novel ligand
of RXFP1 (27).
CTRPs are subjected to posttranslational modifications.
This includes N-linked glycan modifications for CTRP1,
CTRP2, CTRP6, CTRP12, and CTRP15, whereas CTRP3,
CTRP5, CTRP9, CTRP10, CTRP11, and CTRP13 contain other
carbohydrate moieties (28, 30, 46–48, 50, 53, 56, 57). However,
N-glycanase-sensitive glycosylation was not detected for CTRP8
(29). Also, bacterially produced (non-glycosylated) recombinant
proteins, CTRP1, CTRP6, and CTRP8, retain bioactivity,
suggesting that posttranslational glycan modifications are not
required for some of their biological effects. Adiponectin, CTRP2,
CTRP3, CTRP4, CTRP7, CTRP9, CTRP10 contain Ca2+ binding
sites, whereas CTRP1, CTRP5, CTRP6, and CTRP8 lack a Ca2+-
binding element (32, 49, 51). Ca2+ ions were reported to promote
stable trimer formation and oligomerization of adiponectin
(58, 59).
CTRP Members in Cancer
Research on the role of C1q-TNF-related proteins in cancer
is an emerging field and so far CTRP3, CTRP4, and CTRP6
have been associated with tumor-promoting effects. Secreted
CTRP3/cartducin plays a role in cartilage development. Ele-
vated protein expression of CTRP3/cartducin in mouse osteosar-
coma cell lines was shown to promote cell proliferation in a
dose-dependent manner. The MAPK/ERK kinase 1/2 (MEK1/2)
inhibitor, U0126, prevented the mitogenic effect indicating that
CTRP3 induces cell proliferation via ERK1/2-signaling (60).
CTRP3 was also shown to induce migration of mouse endothe-
lial cells in an ERK1/2-dependent manner (39) suggesting a
role in angiogenesis. The receptor mediating the effects of
CTRP3/cartducin is unknown. HeLa and HEK293 cells were used
to show that CTRP4 functions as tumor-promoting inflamma-
tory regulator. CTRP4 overexpression increased NFκB activa-
tion in a dose-dependent manner and induced transcriptional
activity of the NFκB target TNF-α. In human HepG2 hep-
atocarcinoma cells, secreted CTRP4 and recombinant CTRP4
caused enhanced STAT3Tyr705 phosphorylation and increased
IL6 and TNF-α secretion dose-dependently with a maximal
stimulation at 4 ng/ml. Interestingly, increased expression of
CTRP4 upon IL-6 exposure indicated a positive feedback regu-
lation in cancer cells (61). Immunoreactive CTRP6 was detected
in human hepatocellular carcinoma tissue specimens and was
localized to hepatocellular carcinoma cells and to endothe-
lial cells within the tumor. Recombinant CTRP6 increased
Akt phosphorylation in isolated liver endothelial cells and this
signaling was mediated via the C-terminal C1q domain of
CTRP6. Indeed, HepG2 xenografts with exogenous expression
of CTRP6 showed increased tumor angiogenesis and reduced
necrosis (62).
CTRP8 is a Novel RXFP1 Ligand in
Glioblastoma
CTRP8 is evolutionarily highly conserved and secreted as a
homotrimer or heterotrimer with the C1qTNF family mem-
ber C1q-related factor (CRF) (63); the latter also forms het-
erotrimers with CTRP1, CTRP9, and CTRP10 when co-expressed
in cells (29). Until recently, CTRP8 was the least understood
C1q-TNF-related protein member, in part, because Ctrp8 is a
pseudogene in mice and PCR analysis revealed restricted expres-
sion of CTRP8 in human lung and testis (29). We recently
identified CTRP8 as a novel ligand for RXFP1 in human
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glioblastoma cells (27).Humanpatient-derived glioblastoma (GB)
cells and established GB cell lines express RXFP1, but lack the
classical RXFP1 ligands, RLN1 and RLN2. We demonstrated the
expression and secretion of CTRP8 in patient GB cells and dis-
covered that RXFP1 serves as a novel receptor for CTRP8 in
GB. CTRP8 and RLN2, as well as two biologically active pep-
tides homologous to a peptide sequence within the N-terminal
region of the C1q globular domain of human CTRP8, P59, and
P74 (54, 55), activated RXFP1 by inducing cAMP signaling and
PI3K–PKCζ/PKCδ–ERK1/2 signaling in GB cells. The RXFP1-
negative U251 GB cell line and HEK293 cells devoid of RXFP1
with exogenous expression of the related receptor RXFP2 did
not respond with increased cAMP levels demonstrating a spe-
cific RXFP1-mediated signaling. Furthermore, the increased cell
motility by CTRP8, P59, and P74 showed a dose–response and
was critically dependent on RXFP1. RXFP1 activation by CTRP8,
P59, and P74 increased cathepsin-B protein production and secre-
tion, which mediated the RXFP1-induced enhanced GB cell inva-
siveness through laminin matrices. Specific inhibitors for PKCζ,
PKCδ, PI3K, and cathepsin-B and RNAi-mediated RXFP1 knock-
down abolished GB invasiveness. We demonstrated the inter-
action between RXFP1 and CTRP8 by co-immunoprecipitation
of epitope-tagged HA-RXFP1 and CTRP8-His in HEK293 cells.
Our structural simulation studies predicted that the amino acid
sequence “YAAFSVG” present in the P59 and P74 peptides and
located within the N-terminal C1q globular domain of CTRP8
were likely interacting with the leucine-rich repeats (LRR) 7 and
8 of RXFP1 (27). We dismissed the possibility of the formation of
CTRP8/CRF heterotrimers because GB cells were devoid of the
CTRP8 hetero-oligomerization partner CRF (29). Importantly,
competitive binding assays demonstrated that a small peptide
derived from the N-terminal region of the globular C1q domain
of human CTRP6 successfully blocked the PI3K–PKCζ/PKCδ-
mediated increase in cathepsin B secretion and cell motility (27).
Summary and Prospective Goals
The discovery of CTRP8 as RXFP1 agonist in brain cancer is novel
for a number of reasons: (i) RXFP1 is the first receptor to be
identified for any of the CTRP members; (ii) CTRP8 is the first
RXFP1 ligand, which is not structurally related to the relaxin-
like family; (iii) the CTRP8–RXFP1 ligand–receptor system is a
novel player in brain tumor; (iv) our discovery of a competitor
peptide resembling a linear peptide sequence at the transition
from the collagen- to the C1q globular domain of CTRP6, a
close relative of CTRP8, provides first intriguing evidence for a
regulatory network of CTRP factors modulating RXFP1 functions
in a tissue-specific context. These findings are the exciting start of
an emerging field in CTRP and RXFP1 research with the potential
to linkmetabolic and immunological functions of CTRPmembers
withmolecularmechanisms in cancer (45). Future cancer research
activities will elucidate the molecular signaling mechanisms and
functional relevance of CTRP-derived RXFP1 regulation in a
variety of tumors. The use of CTRP-based peptides capable of
blocking CTRP8-mediated actions is currently tested for potential
clinical applications.
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